Literature DB >> 11503936

Amelanotic choroidal nevus and melanoma: cytology, tumor size, and pigmentation as prognostic indicators.

D S Lee1, S F Anderson, E M Perez, J C Townsend.   

Abstract

BACKGROUND: Choroidal nevi are fairly common lesions of the posterior pole that can sometimes transform into melanoma, and it is thought that most choroidal melanomas arise from preexisting nevi. Occasionally, these lesions present as nonpigmented or amelanotic variations of their pigmented counterparts. Recent studies suggest a relationship between tumor pigmentation and risk of growth and metastasis, with a better prognosis for lightly pigmented or amelanotic lesions. CASE REPORTS: A case of an amelanotic choroidal nevus and melanoma are presented. In Case 1, a 26-year-old white female was found to have a large amelanotic nevus in the right eye. After 7 years of periodic observation, the lesion has not changed. In Case 2, a 51-year-old white male was diagnosed with a large amelanotic melanoma in the left eye. Due to extensive involvement of the optic nerve, the patient underwent enucleation. Histological evaluation confirmed the lesion as a mixed-cell type malignant amelanotic melanoma.
CONCLUSION: Management of choroidal nevi generally consists of periodic observation, and the most widely accepted management of choroidal melanoma is observation, radiotherapy, and transpupillary thermotherapy or enucleation. The therapeutic modality of choice for melanoma will vary depending on the size, growth, and location of the lesion. In addition, recent studies suggest an association between heavy tumor pigmentation, tumor size, cell type, and risk of metastasis. Although many variables will influence the final treatment option, pigmentation of the lesion should also be considered.

Entities:  

Mesh:

Year:  2001        PMID: 11503936     DOI: 10.1097/00006324-200107000-00010

Source DB:  PubMed          Journal:  Optom Vis Sci        ISSN: 1040-5488            Impact factor:   1.973


  8 in total

1.  [Unclear parapapillary tumor in childhood].

Authors:  E K Altpeter; D Süsskind; K-U Bartz-Schmidt; M H Foerster; S Aisenbrey
Journal:  Ophthalmologe       Date:  2013-10       Impact factor: 1.059

Review 2.  Ocular melanoma: an overview of the current status.

Authors:  Predrag Jovanovic; Marija Mihajlovic; Jasmina Djordjevic-Jocic; Slobodan Vlajkovic; Sonja Cekic; Vladisav Stefanovic
Journal:  Int J Clin Exp Pathol       Date:  2013-06-15

3.  Long term ultrasonic follow up of choroidal naevi and their transformation to melanomas.

Authors:  I Kaiserman; N Kaiserman; J Pe'er
Journal:  Br J Ophthalmol       Date:  2006-05-03       Impact factor: 4.638

4.  Amelanotic Uveal Melanomas Evaluated by Indirect Ophthalmoscopy Reveal Better Long-Term Prognosis Than Pigmented Primary Tumours-A Single Centre Experience.

Authors:  Anna Markiewicz; Piotr Donizy; Monika Nowak; Mateusz Krzyziński; Martyna Elas; Przemysław M Płonka; Jolanta Orłowska-Heitzmann; Przemysław Biecek; Mai P Hoang; Bożena Romanowska-Dixon
Journal:  Cancers (Basel)       Date:  2022-06-01       Impact factor: 6.575

5.  White matter: A good reference for the signal intensity evaluation in magnetic resonance imaging for the diagnosis of uveal melanoma.

Authors:  Pornrujee Hirunpat; Nuttha Sanghan; Siriporn Hirunpat
Journal:  Neuroradiol J       Date:  2020-12-02

6.  Presumed choroidal metastasis from soft tissue myoepithelial carcinoma.

Authors:  Michelle M Hui; Rohan Merani; Fiona Bonar; Angela M Hong; Adrian T Fung
Journal:  Am J Ophthalmol Case Rep       Date:  2019-02-22

Review 7.  Choroidal sarcoid granuloma: a case report and review of the literature.

Authors:  Dany G Hage; Charbel H Wahab; Wajiha J Kheir
Journal:  J Ophthalmic Inflamm Infect       Date:  2022-09-29

8.  Analysis of local recurrence causes in uveal melanoma patients treated with 125I brachytherapy - a single institution study.

Authors:  Joanna Kowal; Anna Markiewicz; Magdalena Dębicka-Kumela; Anna Bogdali; Barbara Jakubowska; Izabella Karska-Basta; Bożena Romanowska-Dixon
Journal:  J Contemp Brachytherapy       Date:  2019-12-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.